CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today outlined its plans for continued sustainable growth across each of its businesses, provided updates on anticipated near-term regulatory milestones, and shared new clinical data at its Analyst Day Meeting. Genzyme’s growth is being driven by increasing sales of existing products, the launch of new treatments, and continued operating leverage from the company’s global infrastructure.
